IBRX270416P00009000
IBRX Apr 16 2027 9.00 Put
optionOPRA
EODOct 14, 2026
2.45USD+22.500%(+0.45)10Vol25OI
Loading…
Underlying
Underlying Price
$8.36
Type
Put
Strike
9
Expiration
Apr 16, 2027
DTE
178d
Moneyness
ITM
Intrinsic
$0.64
IBRX 9 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.37 | +48.00% | 175 | 878 |
| Oct 30, 2026 | 10d | $0.50 | +72.41% | 53 | 599 |
| Nov 6, 2026 | 17d | $0.49 | +2.08% | 1 | 53 |
| Nov 13, 2026 | 24d | $0.75 | +25.00% | 4 | 238 |
| Nov 20, 2026 | 31d | $0.90 | +21.62% | 65 | 1,572 |
| Nov 27, 2026 | 38d | $1.02 | +20.00% | 2 | 5 |
| Dec 18, 2026 | 59d | $1.15 | +0.00% | 405 | 405 |
| Jan 15, 2027 | 87d | $1.62 | +5.88% | 72 | 52,460 |
| Mar 19, 2027 | 150d | $1.84 | -10.68% | 20 | 137 |
| Apr 16, 2027 | 178d | $2.45 | +22.50% | 10 | 25 |
| May 21, 2027 | 213d | $2.35 | +0.00% | 60 | 60 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.